NCT00109538终止3 期
A Pivotal Randomized Study of Lonafarnib Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 47
- 主要终点
- Proportion of subjects who achieved platelet transfusion independence for any 8-consecutive week period after randomization without worsening of RBC transfusion requirements or hemoglobin (untransfused) during the same 8-consecutive-week period.
研究概览
简要总结
The purpose of this study is to assess the benefit of lonafarnib (versus placebo) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). Benefit will be measured by achievement of platelet transfusion independence for at least 8-consecutive weeks, and without simultaneous worsening of hemoglobin and/or need for red blood cell (RBC) transfusion. Additional endpoints will be hematologic response (which includes complete remission, partial remission, hematologic improvement), number of RBC transfusions, bleeding events, infections and safety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed MDS (RA, RARS, RAEB, RAEB-T) or CMML according to FAB classification.
- •Platelet transfusion dependence (requiring 1 to 8 platelet transfusion events every 4 week period (Day 84 to Day 57, Day 56 to Day 29, and Day 28 to Day 1) over an 8-week retrospective and 4-week prospective screening period).
- •The individual number of platelet transfusion events during the three 4-weekly periods (Day 84 to Day -57; Day -56 to Day 29; Day -28 to Day -1) must not differ by greater more than 2 from the average number of platelet transfusion events during the 12 week screening period.
- •If the subject is RBC transfusion dependent, the number of RBC transfusion events during the three 4-weekly periods (Days -84 to -57; Day -56 to Day 29 and Day -28 to Day -1) must not differ by more than 2 from the average number of RBC transfusion events during this 12 week screening period.
- •ECOG PS 0-2.
排除标准
- •Subjects with chemotherapy/radiotherapy-associated secondary MDS.
- •<12 Weeks (prior to Day-1 Randomization) from any investigational drug use, any chemotherapy, radiotherapy, immunotherapy and any other treatment or MDS/CMML other than best supportive care.
- •Hx of bone-marrow or peripheral stem-cell transplantation or treatment with donor lymphocyte infusion.
- •Hx of AML.
- •Known hx of immune thrombocytopenic purpura.
- •Marked baseline prolongation of QTc interval, CTCAE Grade >=
- •Use of ketokonazole within 72 hours prior to study drug administration.
研究组 & 干预措施
Lonafarnib
Experimental
Lonafarnib 200 mg twice daily, oral, continuously
干预措施: Lonafarnib (Drug)
Placebo
Placebo Comparator
Placebo, BID, oral
干预措施: Placebo (Other)
结局指标
主要结局
Proportion of subjects who achieved platelet transfusion independence for any 8-consecutive week period after randomization without worsening of RBC transfusion requirements or hemoglobin (untransfused) during the same 8-consecutive-week period.
时间窗: Any 8-consecutive week period after randomization
次要结局
- Hematologic response rate (CR, PR, HI), number of RBC transfusion events during a 4-week period, active bleeding events (number and severity), number of CTCAE Grade 3 and 4 infections and days of acute intervention, and safety.(Any 8-consecutive week period after randomization)
研究者
相似试验
进行中（未招募）
1 期
A Pivotal Randomized Study of Lonafarnib (SCH66336) Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia - A pivotal study in CMML/MDSPlatelet Transfusion Dependence in Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) according to FAB criteriaEUCTR2004-004685-32-GRSchering-Plough Research Institute200
进行中（未招募）
1 期
A Pivotal Randomized Study of Lonafarnib (SCH66336) Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia - A pivotal study in CMML/MDSPlatelet Transfusion Dependence in Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) according to FAB criteriaEUCTR2004-004685-32-CZSchering-Plough Research Institute200
进行中（未招募）
1 期
A Pivotal Randomized Study of Lonafarnib (SCH66336) Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia - A pivotal study in CMML/MDSPlatelet Transfusion Dependence in Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) according to FAB criteriaEUCTR2004-004685-32-ATSchering-Plough Research Institute200
进行中（未招募）
不适用
A Pivotal Randomized Study of Lonafarnib (SCH66336) Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia - A pivotal study in CMML/MDSPlatelet Transfusion Dependence in Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) according to FAB criteriaEUCTR2004-004685-32-DESchering-Plough Research Institute200
进行中（未招募）
1 期
A pivotal randomized study of Lonafarnib (SCH 66336) versus placebo in the treatment of subjects with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who are platelet transfusion dependent with or without anemia.EUCTR2004-004685-32-ITSCHERING-PLOUGH200